Compare BARK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BARK | VNDA |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 289.0M |
| IPO Year | N/A | 2006 |
| Metric | BARK | VNDA |
|---|---|---|
| Price | $0.66 | $6.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.50 | ★ $14.00 |
| AVG Volume (30 Days) | 709.6K | ★ 1.3M |
| Earning Date | 11-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $451,690,000.00 | $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | $5.02 | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $0.63 | $3.81 |
| 52 Week High | $2.32 | $6.88 |
| Indicator | BARK | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 63.55 |
| Support Level | $0.63 | $4.89 |
| Resistance Level | $0.70 | $6.88 |
| Average True Range (ATR) | 0.03 | 0.39 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 34.88 | 70.10 |
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.